Avelumab is a promising new therapeutic agent for patients with metastatic Merkel cell carcinoma, a rare and aggressive type of neuroendocrine tumor of the skin.
Merck KGaA and Pfizer Inc.announced that the FDA has accepted for Priority Review the Biologics License Application (BLA) for avelumab,...
This is a multicenter, international, single-arm, open-label, Phase 2 trial to evaluate the efficacy and safety of avelumab in subjects with metastatic Merkel cell carcinoma (MCC).
Merck and Pfizer Inc. announced that the European Commission (EC) has grantedmarketing authorization for Bavencio (avelumab) as a monotherapy for...
Merck KGaA and Pfizer Inc. announced that the European Medicines Agency (EMA) has validated for review Merck�s Marketing Authorization Application...
Merck and Pfizer Inc. announced that the FDA has approved Bavencio (avelumab) Injection 20 mg/mL, for intravenous use, for the...
The National Institute for Health and Care Excellence (NICE) has published draft guidelines recommending Bavencio (avelumab), from Merck KGaA and...
BeiGene, Ltd. announced that the FDA has approved Tevimbra (tislelizumab-jsgr) as monotherapy for the treatment of adult patients with unresectable or metastatic esophageal squamous cell carcinoma (ESCC) after prior systemic chemotherapy that did not include a PD-(L)1 inhibitor . Tevimbra will be available in the U.S. in the second half of 2024.
Merck KGaA, Darmstadt, Germany, and Pfizer announced the initiation of two Phase III studies of avelumab,(MSB 0010718C), an investigational, fully...
Incyte announced that the FDA has approved Zynyz (retifanlimab-dlwr), a humanized monoclonal antibody targeting programmed death receptor-1 (PD-1), for the treatment of adults with metastatic or recurrent locally advanced Merkel cell carcinoma (MCC)